ADVERTISEMENT
2 /3 FREE ARTICLES LEFT THIS MONTH Remaining
Chemistry matters. Join us to get the news you need.

If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)

ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.

ENJOY UNLIMITED ACCES TO C&EN

Pharmaceuticals

Genentech Invests In Singapore ...

April 2, 2007 | APPEARED IN VOLUME 85, ISSUE 14

Genentech will build a $140 million biologics plant in Singapore. Expected to open in 2010, the plant will be the first in Singapore to make microbial fermentation-based pharmaceuticals. It will employ 100 people and initially produce Genentech's Lucentis treatment for wet macular degeneration. The biologics plant will join three already under construction in Singapore. GlaxoSmithKline is building a vaccines facility, and contract manufacturer Lonza is constructing two facilities, one of which Genentech has an option to acquire.

X

Article:

This article has been sent to the following recipient:

Leave A Comment

*Required to comment